Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA. 1 breakthrough …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …